American Express vs AstraZeneca: Founders, CEOs and History

Company facts

Founders

CEOs and their tenures

Timeline: American Express and AstraZeneca side by side

1. 1850American Express

   American Express founded in Buffalo, New York

   Henry Wells, William Fargo and John Butterfield merged three competing express businesses on March 18, 1850 to form the American Express Company, an unincorporated joint-stock association capitalized at 150,000 dollars.

2. 1882American Express

   Money order launched

   American Express introduced its own money order, competing directly with the postal money order the United States Post Office had offered since 1864.

3. 1891American Express

   Traveler's cheque invented

   Marcellus Berry created the American Express Traveler's Cheque after president J.C. Fargo struggled to cash letters of credit on a European trip in 1890.

4. 1913AstraZeneca

   Astra AB Founded in Södertälje, Sweden

   400 doctors and apothecaries establish Astra AB to manufacture pharmaceuticals for the Swedish market, creating the foundation for what would become one of Europe's largest drug companies.

5. 1917American Express

   Federal control of the express industry

   Federal control of the railroads began in December 1917, and in 1918 the domestic express operations of American Express and its rivals were consolidated into the American Railway Express Company.

6. 1958American Express

   First American Express charge card

   American Express issued its first charge card on October 1, 1958, printed on paper with a 6 dollar annual fee, after signing up more than 250,000 card members before launch.

7. 1966American Express

   Gold Card introduced

   American Express launched the Gold Card in 1966 for higher-spending executives and frequent travelers, the first tier above the standard card and the start of the graded premium lineup that later added the Platinum Card and the Centurion Card.

8. 1984American Express

   Platinum Card launched during the financial supermarket build-out

   American Express introduced The Platinum Card by invitation in 1984 with a 250 dollar annual fee, creating the ultra-premium card category.

9. 1993American Express

   Harvey Golub refocuses the company

   Harvey Golub became chief executive in 1993 and unwound the conglomerate: the Shearson brokerage went to Primerica's Smith Barney and The Boston Company to Mellon Bank in 1993, and Lehman Brothers was spun off in 1994.

10. 1993AstraZeneca

    Zeneca Group Spun Off from ICI

    Imperial Chemical Industries demerges its pharmaceuticals and agrochemicals businesses to form Zeneca Group PLC, with initial products including Zestril, Nolvadex, and Zoladex generating approximately $3.2 billion in annual sales.

11. 1999American Express

    Centurion Card launched

    American Express created the Centurion Card in 1999, an invitation-only metal card that became the top tier of its lineup. The company has never published its fee schedule, and the product functions mainly as a positioning device for the cards below it.

12. 1999AstraZeneca

    Astra and Zeneca Merge to Form AstraZeneca

    The all-share merger of equals completes on 6 April 1999, creating AstraZeneca PLC.

13. 2000AstraZeneca

    Nexium Launch Replaces Prilosec

    AstraZeneca launches Nexium (esomeprazole), the single-isomer successor to Losec/Prilosec, in Europe in 2000 and in the United States in 2001 after FDA approval on 20 February 2001.

14. 2001American Express

    Kenneth Chenault becomes chief executive

    Kenneth Chenault became chief executive in January 2001, weeks before the September 11 attacks damaged the company's lower Manhattan operations and cut travel spending sharply.

15. 2006AstraZeneca

    Acquisition of Cambridge Antibody Technology

    AstraZeneca agrees in May 2006 to buy Cambridge Antibody Technology for 1,320 pence a share, valuing the UK biotech at 702 million pounds or about $1.32 billion.

16. 2007AstraZeneca

    Acquisition of MedImmune for $15.6 Billion

    AstraZeneca acquires MedImmune for $15.6 billion, entering the biologics market and gaining the Synagis respiratory syncytial virus franchise and antibody technology platforms. The Gaithersburg facility becomes one of three global R&D centres.

17. 2008American Express

    Conversion to a bank holding company

    On November 10, 2008 the Federal Reserve Board approved applications by American Express Company and American Express Travel Related Services to become bank holding companies, on conversion of American Express Centurion Bank from an industrial loan company int…

18. 2012AstraZeneca

    Pascal Soriot Appointed CEO

    Pascal Soriot joins AstraZeneca as Chief Executive Officer on October 1, 2012, with a base salary of $1.4 million and a mandate to reverse declining revenue and R&D productivity through science-led investment.

19. 2014AstraZeneca

    Pfizer Hostile Takeover Rejected

    AstraZeneca's board rejects a $117 billion hostile takeover offer from Pfizer, with Soriot arguing that the undervaluation would destroy long-term shareholder value and pipeline potential.

20. 2014AstraZeneca

    Acquisition of Almirall Respiratory Portfolio

    AstraZeneca acquires the respiratory portfolio of Spanish pharmaceutical company Almirall for approximately $2.1 billion, strengthening the company's position in COPD and asthma with products including Eklira and pipeline candidates that become Breztri.

21. 2015AstraZeneca

    Tagrisso Approved for EGFR-Mutated Lung Cancer

    The FDA approves Tagrisso (osimertinib) in November 2015 for metastatic EGFR T790M mutation-positive non-small cell lung cancer, the first product from Soriot's reinvestment strategy to reach market.

22. 2016American Express

    Costco co-brand ends

    Costco moved its United States co-branded card to Citigroup and Visa on June 20, 2016, ending a 16-year exclusive relationship after the two sides failed to agree terms, and stopped accepting American Express cards in its warehouses.

23. 2017AstraZeneca

    Imfinzi Approved Based on PACIFIC Trial

    The FDA approves Imfinzi (durvalumab) for unresectable stage III non-small cell lung cancer after chemoradiation, based on PACIFIC trial data showing survival benefits.

24. 2018American Express

    Stephen Squeri becomes chairman and chief executive

    Stephen Squeri succeeded Kenneth Chenault in February 2018 after more than three decades inside the company, including spells as chief information officer and group president of Global Corporate Services.

25. 2020American Express

    Pandemic hits travel and entertainment spending

    COVID-19 restrictions cut the travel and entertainment spending American Express depends on, and total revenues net of interest expense fell from 43.6 billion dollars in 2019 to 36.1 billion dollars in 2020, with net income down to 3.1 billion dollars.

26. 2020AstraZeneca

    COVID-19 Vaccine Development with Oxford University

    AstraZeneca partners with the University of Oxford to develop and manufacture the Vaxzevria COVID-19 vaccine, distributing billions of doses globally at nonprofit pricing during the pandemic peak.

27. 2021AstraZeneca

    Acquisition of Alexion Pharmaceuticals for $39 Billion

    AstraZeneca completes the $39 billion acquisition of Alexion on July 21, 2021, entering the rare disease market with Soliris and Ultomiris and creating a dedicated rare disease unit headquartered in Boston.

28. 2023AstraZeneca

    CinCor Pharma Acquired for up to $1.8 Billion

    AstraZeneca agrees on 9 January 2023 to acquire CinCor Pharma for up to $1.8 billion, $26 per share in cash plus a $10 per share contingent value right, to gain baxdrostat, an aldosterone synthase inhibitor for resistant hypertension.

29. 2024American Express

    Tock acquisition widens the dining platform

    American Express agreed in June 2024 to buy Tock, a reservation, table and event management platform, from Squarespace for 400 million dollars in cash, pairing it with Resy, which it had bought in 2019.

30. 2024AstraZeneca

    Total Revenue Reaches $54.073 Billion

    AstraZeneca reports Total Revenue of $54.073 billion for fiscal year 2024, an 18% increase at actual rates and 21% at constant exchange rates, with 16 blockbuster medicines, 74 regulatory events, and 24 pipeline progression events.

31. 2024AstraZeneca

    Fusion Pharmaceuticals and Gracell Acquisitions

    AstraZeneca acquires Fusion Pharmaceuticals for $2 billion to access radiopharmaceutical technology and Gracell Biotechnologies for $1.2 billion for cell therapy manufacturing, expanding modality diversity into radiopharmaceuticals and CAR-T.

32. 2025American Express

    Platinum refresh and record FY2025 results

    American Express unveiled refreshed United States Consumer and Business Platinum Cards on September 18, 2025, raising the annual fee from 695 dollars to 895 dollars and adding statement credits it values at over 3,500 dollars a year.

33. 2025AstraZeneca

    Total Revenue Reaches $58.739 Billion

    AstraZeneca reports Total Revenue of $58.739 billion for fiscal year 2025, an 8% increase at constant exchange rates, with 16 positive Phase III readouts, 43 major market approvals, and a commitment to invest $50 billion in U.S. manufacturing by 2030.

34. 2025AstraZeneca

    EsoBiotec Acquired for Up to $1 Billion

    AstraZeneca acquires Belgian biotech EsoBiotec for up to $1 billion to access in vivo cell therapy technology, eliminating the need for ex vivo manufacturing in CAR-T therapies.

35. 2025AstraZeneca

    $50 Billion US Manufacturing and R&D Commitment

    AstraZeneca announces on 21 July 2025 that it will invest $50 billion in United States manufacturing and research by 2030, including a new Virginia facility later raised to $4.5 billion.

36. 2026AstraZeneca

    Ordinary Shares Begin Trading on the NYSE

    AstraZeneca ordinary shares start trading on the New York Stock Exchange on 2 February 2026 under the ticker AZN, after the American Depositary Share programme and certain debt securities stopped trading on Nasdaq on 30 January 2026.

37. 2026AstraZeneca

    Baxfendy Approved in the US for Hypertension

    The FDA approves Baxfendy (baxdrostat) in May 2026 as the first aldosterone synthase inhibitor for hypertension, used in combination with other antihypertensives in adults who are not adequately controlled.

38. 2026AstraZeneca

    $15 Billion China Investment Through 2030

    AstraZeneca announces on 29 January 2026 that it will invest $15 billion in China through 2030 to expand manufacturing and research, in a market that is its second largest and about 12% of revenue.

Acquisitions

Questions about American Express vs AstraZeneca